Payment overview · 2025
General Payments
$63,475.20
145 reported records · 12 companies
Healthcare provider profile · identity verified
Daniel Nathan Berger, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · SANTA BARBARA, CA · NPI 1669407680
Verified facts
What the public records show
CMS Open Payments records show Daniel Nathan Berger, MD received $63,475.20 in general payments during 2025 across 145 reported records.
Novo Nordisk Inc accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 508 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37,291.36 | 58.8% | 29 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15,979.74 | 25.2% | 43 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $8,391.50 | 13.2% | 12 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $913.79 | 1.4% | 35 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $341.72 | 0.5% | 13 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $140.73 | 0.2% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $118.10 | 0.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $115.41 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $64.22 | 0.1% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $57.98 | 0.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.96 | 0.1% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $21.69 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,742.06 | 13 |
| Compensation for serving as faculty or as a speaker for a medical education program | $17,323.00 | 16 |
| Travel and Lodging | $10,641.02 | 21 |
| Food and Beverage | $3,716.87 | 93 |
| Education | $32.27 | 1 |
| Long term medical supply or device loan | $19.98 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37,209.63 | 26 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15,959.76 | 42 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $8,359.30 | 10 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $8,359.30 | 10 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $789.94 | 34 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $341.72 | 13 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $140.73 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $123.85 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $118.10 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $118.10 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $118.10 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $64.22 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $57.98 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $19.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 508 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
133 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
508 | 101 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 957 | 283 |
| Synthroid | Levothyroxine Sodium | 549 | 147 |
| Ozempic | Semaglutide | 508 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 392 | 122 |
| Metformin Hcl Er | Metformin Hcl | 294 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 88 |
| Trulicity | Dulaglutide | 165 | 39 |
| Mounjaro | Tirzepatide | 162 | 34 |
| Jardiance | Empagliflozin | 158 | 47 |
| Farxiga | Dapagliflozin Propanediol | 133 | 35 |
| Metformin Hcl | Metformin Hcl | 127 | 44 |
| Tresiba Flextouch U-100 | Insulin Degludec | 123 | 53 |
| Liothyronine Sodium | Liothyronine Sodium | 121 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 121 | 58 |
| Kerendia | Finerenone | 120 | 28 |
| Losartan Potassium | Losartan Potassium | 118 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 41 |
| Repaglinide | Repaglinide | 108 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 101 | 36 |
| Simvastatin | Simvastatin | 97 | 30 |
| Ezetimibe | Ezetimibe | 96 | 36 |
| Testosterone | Testosterone | 86 | 23 |
| Alendronate Sodium | Alendronate Sodium | 70 | 23 |
| Methimazole | Methimazole | 69 | 20 |
| Repatha Sureclick | Evolocumab | 68 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 19 |
| Novolog Flexpen | Insulin Aspart | 61 | 25 |
| Hydrocortisone | Hydrocortisone | 56 | 13 |
| Januvia | Sitagliptin Phosphate | 56 | 20 |
| Rybelsus | Semaglutide | 55 | 12 |
| Glimepiride | Glimepiride | 50 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 14 |
| Armour Thyroid | Thyroid,pork | 45 | suppressed |
| Calcitriol | Calcitriol | 43 | 13 |
| Lisinopril | Lisinopril | 39 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 11 |
| Humalog | Insulin Lispro | 38 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 37 | 13 |
| Invokana | Canagliflozin | 37 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 36 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Levoxyl | Levothyroxine Sodium | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | 13 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Afrezza | Insulin Regular, Human | 20 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Baqsimi | Glucagon | 17 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Gabapentin | Gabapentin | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Genotropin | Somatropin | 16 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Somatuline Depot | Lanreotide Acetate | 13 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63,475.20 · 145 records | Novo Nordisk Inc | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, FREESTYLE INSULINX, FREESTYLE LIBRE 3, GVOKE HYPOPEN, LEQVIO, OMNIPOD, Ozempic, RECORLEV, TWIIST, TZIELD, Wegovy, XYOSTED, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error